Pharmacology for Anaesthesia and Intensive Care

P1: PSB Printer: Yet To Come
9780521704632ind CUFX213A/Peck 9780521618168 December 29, 2007 17:19

378 Index

total intravenous anaesthesia (TIVA), 81 –82

safety, 83 –84

train-of-four,177f, 179

tramadol, 147 –148

effects, 148

interactions, 148

kinetics, 148

mechanism of action, 148

presentation, 148

tranexamic acid, 346

transdermal route, 12 –13

tranylcypromine, 277

triamcinolone, 353

triazoles, 332 –333

tricyclic antidepressants, 274 –276

effects, 275

mechanism of action, 275

overdose, 275 –276

phenytoin treatment, 279

uses, 274

triiodothyronine (T 3 ), 216, 355–357

kinetics, 357

trimetaphan, 268 –269

tubocurarine, 90 , 188–189

two-compartment models, 68 –70

tyrosine, 87 –88

tyrosine kinase, membrane, 30 –31

urokinase, 345

vacuum insulated evaporator (VIE), 128

valdecoxib, 161

kinetics, 161

vancomycin, 322 –323

oral, 8

vancomycin-resistant enterococci (VRE), 311 ,

322

vanillylmandelic acid

adrenaline metabolism, 203

noradrenaline kinetics, 204

vasodilators, 246 –257

activity and local anaesthetics, 166

calcium channel antagonists, 252 –255

potassium channel activators, 251 –252

sodium nitroprusside, 246 –249

see alsonitrates

vecuronium, 35 –37, 41–42, 90, 185–186

venlafaxine, 276

ventricular tachyarrhythmias, 229 , 237–238

with supraventricular tachyarrhythmias,

239 –245

verapamil, 234 –235, 252–253

kinetics, 235

mechanism of action, 234

presentation, 234

side-effects, 234 –235

uses, 234

vigabatrin, 281

vitamin B 12 , 248–249

vitamin K, warfarin therapy, 342 –343

volatile anaesthetic agents, 13

racemic mixtures, 48

volume of distribution, 72 –73

constant relationships, 75

plasma concentration, 75 –76

total, 72 –73

vomiting, 282

domperidone use in children, 296

neural inputs,283f

physiology, 282

see alsoantiemetics

vomiting centre, 282

warfarin, 342 –344

actions,343f

drug interactions, 343

amiodarone, 41

kinetics, 344

mechanism of action, 342 –343

side-effects, 343

therapy monitoring, 344

uses, 342

wash-out curve, 52 –54

asymptote, 52 –54

semilogarithmic transformation,59f

Wolff–Parkinson–White syndrome, 234 –235

xanthenes, 98

xenon, 114 , 127t, 128t

effects,127t, 128t

elimination,128t

manufacture,127t

ximelagatran, 344

kinetics, 344

xylidine, 98

yohimbine, 220

zaleplon, 274

zero-order kinetics, 78 –79, 79f

zidovudine, 334

zolpidem, 274

zopiclone, 274